DSIP (Delta Sleep-Inducing Peptide) vs Selank

25 nmol/kg (about 1.5 mg for a 70 kg adult)

Single slow infusion · Study setting only — longest trial ran 7 consecutive nights

The only DSIP dose with human evidence. Source class: clinical trial protocol. Five published trials used 25 nmol/kg as a slow intravenous infusion under medical supervision — about 1.5 mg for a 155 lb (70 kg) adult [1][3][4][6][7] — and one used total doses of 3 to 4 mg the same way [8]. Results were mixed: two independent double-blind trials found the sleep benefit small or not clinically significant [6][7]. See the evidence note.

100 mcg

Once daily, 1 hour before bed · 1–2 weeks

Source class: community practice, not peer-reviewed. No human study has used subcutaneous DSIP at any dose. This figure comes from vendor and forum protocols, not from the trial literature — the published human dose is roughly 1.5 mg intravenously, about 15x this amount by a different route. [1][2]

200 mcg

Once daily, 1 hour before bed · 4–6 weeks

Source class: community practice, not peer-reviewed. The most commonly circulated figure for subcutaneous use, and it appears in no published study. Subcutaneous DSIP has never been tested in humans, so neither its absorption nor its safety by this route is known. [1][2]

300 mcg

Once daily, 1 hour before bed · 2–4 weeks

Source class: community practice, not peer-reviewed. Upper end of circulated subcutaneous figures. No controlled trial supports this dose, this route, or escalation between these steps — the three subcutaneous rows are reported practice, not a studied titration. [1][2]

200–300 mcg

Once daily before bed · 2–6 weeks

Source class: community practice, not peer-reviewed. Intranasal DSIP has no published human study. Nasal absorption of a 9-amino-acid peptide has not been characterised, so a per-dose amount copied from the injectable route has no basis. [1]

Registered label dose

900 mcg/day total (3 doses of 300 mcg)

2 drops in each nostril, 3 times daily · Registered label dose

The approved dose on the Russian registration (ЛРС-003338/09): 2 drops in each nostril, three times a day. At 75 mcg per drop that is 300 mcg per administration and 900 mcg across the day, taken as a 14-day course that can be repeated after 1-3 weeks [7]. Human evidence, registered label.

Highest dose studied

2,700 mcg/day total (3 doses of 900 mcg)

900 mcg (12 drops) 3 times daily · Highest dose studied

The top of the range the developing institute describes as optimal — single doses of 300-900 mcg, 900-2,700 mcg a day split across three administrations — and the dose used in the multicentre generalised-anxiety and neurasthenia trial, where 2,700 mcg/day was compared against medazepam 30 mg/day for 14 days [9]. Because the label caps a single administration at 2-3 drops per nostril, a 900 mcg dose is given as 2-3 drops per nostril with the rest 15 minutes later [7]. Human evidence, trial protocol.

Community suggestion — not a studied protocol

300-500 mcg per injection

Once daily · Community suggestion — not a studied protocol

Community-reported, not peer-reviewed. No human study has tested subcutaneous selank and the registered product is nasal drops only [7], so this range comes from community and clinical-practice reports rather than a trial — there is no published safety or effectiveness data behind it. Two things worth knowing before choosing the route. The nasal spray is absorbed almost completely, with 92.8% of the dose reaching the bloodstream within 30 seconds [7], so injecting is not a way to get more of the peptide in. And in mice, the injected and intranasal routes did not act the same: injection shifted GABA-receptor binding while the nasal route shifted NMDA-receptor binding instead, which the authors put down to how each route is absorbed and broken down [13]. That is animal work, and no one has checked whether the same split happens in people.